title: [Pigment epithelial detachment in exudative macular degeneration: clinical characteristics and therapeutic options].
abstract: Vascularized pigment epithelial detachment (PE detachment) can be viewed as a special form of occult choroidal neovascularization (CNV) owing to the natural course of the disease, its specific pathogenesis and its response to various forms of treatment. This applies to serous PE detachment associated with both occult CNV and also with retinal angiomatous proliferation (RAP). A tear in the retinal pigment epithelium (RIP) represents a serious complication of vascularized PE detachment and is often associated with acute vision deterioration that not uncommonly also involves massive subretinal hemorrhaging. The pathomechanism underlying the development of RIP has not yet been completely elucidated. The notion that the PED bursts as a result of the increased pressure stands in contrast to the theory that the CNV contracts and causes scarring which in turn causing secondary RIP. Anti-VEGF therapy is currently the preferred treatment. However, the initial stabilization of visual acuity after treatment could not be confirmed in long-term studies and after 2 years visual acuity deteriorated significantly. Furthermore, optimal VEGF treatment regimens have also not been defined and the criteria for repeated treatment have not been established as yet. Presently, visual deterioration and the presence of subretinal and intraretinal exudates seem to indicate that treatment will be effective. Here, high resolution OCT imaging should help to provide further insight into the matter.
authors.affiliation: Augenabteilung am St. Franziskus-Hospital, Hohenzollernring 74, Münster, Germany. Albrecht.Lommatzsch@web.de
authors.forename: A
authors.initials: A
authors.lastname: Lommatzsch
mesh_terms: D000368:Aged; D016570:Bruch Membrane / Q000503:physiopathology; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D005451:Fluorescein Angiography; D006414:Hematoporphyrin Photoradiation; D006801:Humans; D017075:Laser Coagulation; D010857:Pigment Epithelium of Eye / Q000503:physiopathology; D011379:Prognosis; D012163:Retinal Detachment / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy*; D012166:Retinal Hemorrhage / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D015861:Retinal Neovascularization / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D012167:Retinal Perforations / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D057135:Wet Macular Degeneration / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy*
chemical_list: D042461:Vascular Endothelial Growth Factor A